Takashi Oyama
Overview
Explore the profile of Takashi Oyama including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
62
Citations
1008
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Masuda Y, Honda A, Oyama T, Masamoto Y, Kurokawa M
Int J Hematol
. 2025 Mar;
PMID: 40032737
Fluid retention presenting as effusions in body cavities is sometimes encountered following allogeneic stem cell transplantation (allo-HSCT). It is unclear whether cavity effusions at independent sites may serve as cumulative...
2.
Oyama T, Honda A, Masuda Y, Morita K, Maki H, Masamoto Y, et al.
Clin Transplant
. 2025 Jan;
39(1):e70072.
PMID: 39761366
Background: Pleural effusion and ascites developing after allogeneic hematopoietic stem cell transplantation (allo-SCT) are generally associated with inferior overall survival (OS); however, the prognostic value of pretransplant effusion on transplant...
3.
Nagano Y, Sasaki S, Higashihara A, Oyama T
PLoS One
. 2024 Aug;
19(8):e0302339.
PMID: 39208310
Although understanding the status of sports participation is essential for preventing injuries in young athletes, the level of specialization and relevant information in Japan is unknown. This study aimed to...
4.
Nagayama T, Fujiwara S, Tominaga R, Yokoyama D, Noguchi A, Furuki S, et al.
Leuk Lymphoma
. 2024 May;
65(9):1350-1356.
PMID: 38767307
The tumor microenvironment's cells can promote or inhibit tumor formation, and there are no reports on the CD4/CD8 ratio's association with outcomes post allogeneic hematopoietic stem cell transplantation (allo-HSCT). We...
5.
Oyama T, Fujiwara S, Tominaga R, Yokoyama D, Noguchi A, Furuki S, et al.
Clin Transplant
. 2024 Apr;
38(4):e15313.
PMID: 38581299
Background: The number of CD34 cells in the graft is generally associated with time to engraftment and survival in transplantation using cord blood or allogeneic peripheral blood stem cells. However,...
6.
Yamamoto C, Minakata D, Yokoyama D, Furuki S, Noguchi A, Koyama S, et al.
Transplant Cell Ther
. 2023 Oct;
30(1):118.e1-118.e15.
PMID: 37802181
Despite its promising outcomes, anti-BCMA chimeric antigen receptor T cell therapy (CAR-T) is the most expensive myeloma treatment developed to date, and its cost-effectiveness is an important issue. This study...
7.
Takeyasu S, Morita K, Saito S, Toho M, Oyama T, Obo T, et al.
Int J Hematol
. 2023 Sep;
118(6):745-750.
PMID: 37707761
Myeloid sarcoma is a rare clinical entity that presents as an isolated proliferation of leukemic cells, concurrently with or at relapse of acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), chronic...
8.
Nagayama T, Fujiwara S, Tominaga R, Yokoyama D, Noguchi A, Furuki S, et al.
Clin Transplant
. 2023 Aug;
37(12):e15116.
PMID: 37641561
Background: The early recovery of lymphocyte and monocyte cells is associated with a favorable prognosis after allogeneic stem cell transplantation (allo-HSCT); however, it is not clear whether the balance of...
9.
Oyama T, Yasunaga M, Jona M, Nishikawa M, Yatomi Y, Honda A, et al.
J Clin Exp Hematop
. 2023 Aug;
63(3):187-192.
PMID: 37635085
Thrombocytopenia is a frequent complication in chronic lymphocytic leukemia (CLL). Differentiating autoimmune thrombocytopenia from thrombocytopenia due to bone marrow infiltration is necessary for appropriate treatment, but sometimes difficult. Here we...
10.
Uchitachimoto G, Sukegawa N, Kojima M, Kagawa R, Oyama T, Okada Y, et al.
Sci Rep
. 2023 Jul;
13(1):11820.
PMID: 37479701
Recent studies showed that machine learning models such as gradient-boosting decision tree (GBDT) can predict diabetes with high accuracy from big data. In this study, we asked whether highly accurate...